Dr Reddy Stock

Dr Reddy's Labs Q1 results preview: Analysts said that despite pricing pressures in the US, the company is likely to have recorded steady growth in this segment due to a ramp-up of new products.

Sales in the US, its biggest market, accounting for 37 per cent of revenues, were up 8 per cent year-on-year (YoY) and 12 per cent sequentially, led by five new launches

Weekly Technical Recommendations by Religare Broking Ltd.

The Hyderabad-based company is an outlier among large pharmaceutical producers, having seen a jump in its stock price over the previous year

Earnings were driven by one-off gains

Analysts at Nomura believe there is a strong probability that the company will get approval in the near term for Suboxone & expect initially lower competitive intensity